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Summary
The genomic organization of theCDK2 gene, which overlaps themelanocyte-specific gene SILV/PMEL17, poses an interest-
ing regulatory challenge. We show that, despite its ubiquitous expression, CDK2 exhibits tissue-specific regulation by the
essential melanocyte lineage transcription factor MITF. In addition, functional studies revealed this regulation to be critical
for maintaining CDK2 kinase activity and growth of melanoma cells. Expression levels of MITF and CDK2 are tightly
correlated in primary melanoma specimens and predict susceptibility to the CDK2 inhibitor roscovitine. CDK2 depletion
suppressed growth and cell cycle progression in melanoma, but not other cancers, corroborating previous results. Collec-
tively, these data indicate that CDK2 activity in melanoma is largely maintained at the transcriptional level by MITF, and
unlike other malignancies, it may be a suitable drug target in melanoma.
Introduction per se, suggesting that transcriptional targets beyond pigment
genes are likely important as well. While expression of many
MITF is a basic-helix-loop-helix/leucine-zipper (bHLHZip) tran- melanocytic markers is often lost in melanoma, MITF expression
scription factor whose mutation produces melanocyte defects is usually (if not always) maintained in human melanoma speci-
in mouse (Silvers, 1979) and human (Tassabehji et al., 1994). mens, suggesting that MITF might be particularly important for
MITF belongs to the MYC superfamily of transcription factors melanoma maintenance (reviewed in Chang and Folpe, 2001).
and binds the E box sequences CA(C/T)GTG (Hemesath et al., One particular MITF target likely to be important for viability is
1994; Hodgkinson et al., 1993; Tachibana et al., 1994). The BCL2 (McGill et al., 2002). However, BCL2 cannot fully mediate
three major pigmentation enzymes, TYR, TYRP1, and DCT, are MITF’s proliferation/survival effects, because MITF deficiency
thought to be transcriptional targets of MITF (Bentley et al., produces earlier melanocyte deficiency than Bcl2 knockout. In
addition, BCL2 overexpression cannot rescue clonogenic growth1994; Hemesath et al., 1994; Yasumoto et al., 1994, 1995, 1997),
suggesting that the pigmentation pathway in general is largely in the setting of MITF disruption in melanoma cells (McGill et
al., 2002). Together, these observations suggest the existenceregulated by MITF’s activity. An additional MITF target gene
important for pigmentation is the SILVER/PMEL17 gene (Du et of other target genes that are important for the proliferation/
survival of melanocytes and melanomas.al., 2003), which encodes the GP100/HMB45 antigen commonly
utilized for melanoma diagnosis and immune therapy (Adema One such candidate is cyclin-dependent kinase 2 (CDK2).
Until recently, CDK2 was thought to be a major cell cycle regula-et al., 1993; Wagner et al., 1995). Mutation of Silver/Pmel17
produces a significant pigmentation defect (resembling silver tor, functioning during the G1/S transition and S phase (Ekholm
and Reed, 2000). In vivo, CDK activity is largely regulated posi-color) in mice (Silvers, 1979), further supporting MITF’s role
as a transcriptional regulator of pigmentation. However, MITF tively through association with the appropriate cyclins and nega-
tively by CDK inhibitors. Genomic analysis reveals that the tran-deficiency affects melanocyte viability rather than pigmentation
S I G N I F I C A N C E
Until recently, CDK2 was considered to be one of the essential cell cycle regulators during G1-S transition and S phase progression.
However, Cdk2 null mice develop almost normally, and blockage of CDK2 in colon carcinoma cells and several other cancer types
had minimal effects on their proliferation, suggesting that CDK2 might not be a suitable target for cancer treatments. Our results
suggest that CDK2might be particularly important for melanoma proliferation. These observations also help to explain MITF’s essential
role in melanoma growth. The unique regulation of CDK2 expression in melanoma, correlating with drug sensitivity, may help predict
patients’ responses to CDK2-targeted cancer therapy.
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scriptional start site ofSILVER resides just 796 nucleotides away anoma) and SW480 (colon cancer) cells, the latter lacking sig-
nificant MITF expression. PCR primers spanned the E2 site asfrom theCDK2gene start site (head-to-head orientation) (Adachi
and Lieber, 2002). The TATA-less CDK2 promoter has been well as a negative control (E3 site) near the transcription initiation
site of CDK2. This assay revealed that MITF is bound to thestudied in NIH3T3 mouse fibroblasts (Shiffman et al., 1996).
Multiple transcription factor binding sites have been identified, CDK2 upstream regulatory region, but not the area spanning
the first exon/intron boundary. No PCR products were observedand the sequence spanning100 to108 is sufficient for basal
promoter activity in NIH3T3 cells, specifically attributed to two in controls immunoprecipitated with either no antibody or con-
trol antibodies against BRN2 or CDK2. ChIP was also negativeSP1 sites within this region (Shiffman et al., 1996). In addition,
a serum-responsive cis-element is present in a 1.7 kb segment in SW480 cells (which lack MITF), providing a control for the
specificity of the MITF antibody signal in melanoma cells. These700 bp upstream of the transcriptional start (Shiffman et al.,
1996). results indicate that MITF directly binds the E2 element in mela-
noma cells, consistent with previous evidence that MITF bindsImportantly, CDK2’s role as a key cell cycle regulator has
been challenged recently. In colon cancer cell lines, cell cycle to the same region in regulation of the SILV gene (Du et al.,
2003) and suggesting a direct effect on CDK2 transcription.arrest caused by MAPK inhibition is mediated by CDK4, but
not CDK2 inhibition (Tetsu and McCormick, 2003). Moreover,
inhibition of CDK2 by CDKN1B/p27KIP1, a dominant-negative Transcriptional regulation of endogenous CDK2
by MITF in the melanocyte lineageCDK2, RNAi, or antisense does not prevent these cells from
proliferating (Tetsu and McCormick, 2003). In addition, engi- To investigate whether MITF modulates endogenous CDK2
gene expression in melanocytic cells, early passage primaryneered Cdk2 null mice display no dramatic phenotype other
than sterility of both genders, suggesting that CDK2 is essential human melanocytes and several melanoma cell lines (501mel,
SKMEL5, SKMEL28, UACC62, and A375) were infected withfor meiosis but not mitosis during normal development (Berthet
et al., 2003; Ortega et al., 2003). adenoviruses expressing wild-type MITF, dominant-negative
MITF, or vector control. Quantitative RT-PCR measurementsSince the nearbySILVERgene is expressed in a melanocyte-
restricted fashion, we asked whether its transcriptional regula- revealed that wild-type MITF stimulated expression of CDK2
mRNA, while dominant-negative MITF repressed CDK2 tran-tor, MITF, might also modulate CDK2 expression specifically
in melanocytes. We show that this is indeed the case, using scripts in melanocytes (Figure 2A). Adenoviral infections re-
vealed the same CDK2 regulation by MITF in all five melanomaquantitative RT-PCR measurements of CDK2 mRNA and West-
ern analysis of CDK2 protein upon modulation of MITF levels, cell lines tested (Figure 2A). Western blot analysis (Figures 2B
and 2C) also revealed that wild-type MITF upregulated andchromatin immunoprecipitations (ChIPs), and luciferase reporter
assays. Moreover, CDK2 and MITF expression levels are tightly dominant-negative MITF downregulated expression of endoge-
nous CDK2 protein. In addition, in vitro kinase assays revealedcorrelated in a panel of primary human melanomas and mela-
noma cell lines. Functional studies reveal that CDK2 regulation that dominant-negative MITF dramatically repressed while wild-
type MITF did not significantly augment endogenous CDK2 ki-by MITF is essential for melanoma clonogenic growth. In addi-
tion, CDK2 expression levels correlated closely with sensitivity nase activity (Figure 2B), suggesting that transcriptional regula-
tion of CDK2 by MITF appears to be rate limiting for CDK2to the CDK inhibitor roscovitine. Finally, we confirm recent evi-
dence that CDK2 suppression is well tolerated in other malig- kinase activity in these cells.
We also examined regulation of CDK2 expression via siRNA-nancies, yet find that CDK2 is essential for melanoma clono-
genic growth and that siRNA-mediated depletion of CDK2 mediated knockdown of MITF. This siRNA specifically depleted
MITF but not CDK1, CDK6, or -tubulin in melanoma cells (Fig-suppresses cell-cycle progression and short-term as well as
long-term proliferation of these cells. ure 2D). Consistent with the results from overexpression of dom-
inant-negative MITF, we observed significant reduction of CDK2
protein levels upon depletion of MITF (Figure 2D). In addition,Results
this siRNA was able to downregulate two known MITF down-
stream targets, BCL2 and SILV (Figure 2D). To further demon-Human CDK2-SILV locus
Recently, we identified SILV as a transcriptional target of MITF strate the specificity of this siRNA, we examined its effects
in a colon carcinoma cell line (SW480) that does not express(Du et al., 2003). BLAST searching (Altschul et al., 1997) mapped
its transcriptional initiation site to 796 bp away from the tran- endogenous MITF and observed no changes in CDK2 or
-tubulin expression levels.scriptional start of CDK2 (head to head) (Adachi and Lieber,
2002) (Figure 1A). Of three E boxes matching the MITF consen-
sus within this region, one was found to reside within a 111 bp E box-dependent modulation of CDK2
reporters by MITFregion 90% identical between mouse and man, and this E box
To further assess the directness of this regulation, luciferasewas found to be targeted by MITF for regulation of SILV expres-
reporters containing the upstream CDK2 region were trans-sion in melanocytes (Du et al., 2003). Due to its proximity to the
fected into 501mel human melanoma cells with or without co-CDK2 gene, we therefore asked whether this element, and MITF,
transfected MITF. As shown in Figure 3A, the E2 site was criticalmight similarly regulate CDK2 expression in melanocytic cells
for MITF responsiveness, while E1 appeared to be dispensable.(Figure 1A).
Mice heterozygous for dominant-negative Mitf alleles
(MitfMi-Or and MitfMi-mi ) display ventral spotting (white belly spot)In vivo binding of MITF to the CDK2/SILV E2 region
To investigate in vivo occupancy by MITF of theCDK2 upstream due to absence of melanocytes, whereas those heterozygous
for null (Mitfmi-ce and Mitfmi-VGA9 ) or hypomorphic (Mitfmi-vit ) allelesregulatory region, ChIP was carried out from multiple cell types.
Shown in Figure 1B are representative results from 501mel (mel- exhibit normal pigmentation, indicating that dominant-negative
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Figure 1. The human CDK2-SILV locus and bind-
ing of MITF to CDK2 cis-regulatory regions
A: The human CDK2-SILV locus and potential en-
hancer element. Exon ones are denoted by
large arrows and reveal that the genes are en-
coded in a head-to-head configuration. Three
E box consensus elements are highlighted in red
and named E1–E3. The conserved DNA se-
quence surrounding the E2 site is shown in detail
using a larger font. Predicted binding sites for
additional transcription factors are underlined
and annotated.
B: Binding of MITF to the endogenous, overlap-
pingCDK2and SILVcis-regulatory region in mela-
noma cells versus colon carcinoma cells. Chro-
matin immunoprecipitations from 501mel or
SW480 cells were performed as described in the
Experimental Procedures. PCR products were re-
solved on 2% agarose by electrophoresis. DNA
from lysates prior to immunoprecipitation was
used as positive input control. The E2 primer set
amplifies the E2-regulatory region, which is im-
portant for gene expression, while the E3 primer
set amplifies a nearby region that is dispensable
for gene expression (negative control), based
upon reporter assays (see below and data not
shown).
but not null mutants could interfere with the function of the wild- contrast, the recessive mutant Mitfmi-ce did not interfere with the
wild-type protein (Figure 3B).type allele. To assess whether the behavior of these mutant
alleles would be reflected in transcriptional assays, CDK2 pro- To examine whether the E boxes are required for CDK2
transcription in the chromatin (integrated) context, the CDK2moter luciferase reporters were cotransfected with mixtures of
wild-type and mutant Mitf alleles (Figure 3B). These Mitf alleles upstream regulatory region was fused to the puromycin resis-
tance gene and transfected into melanoma cells (Figure 3C).have been used previously to demonstrate the transcriptional
regulation of Cathepsin K by MITF in osteoclasts (Motyckova et Here, using colony formation (reflecting integrated, chroma-
tinized reporters), the E2 element was also found to be essentialal., 2001). The different versions of MITF were seen to be expressed
at approximately comparable levels after transfection (Supplemen- for transcriptional activity (Figure 3C). We also performed these
colony formation assays in SW480, where there is no endoge-tal Figure S1 at http://www.cancercell.org/cgi/content/full/
6/6/565/DC1/). Consistent with their dominant phenotype, nous MITF expression, and found that a comparable number of
colonies were formed with the wild-type and mutant constructs.MitfMi-Or and MitfMi-mi repressed cotransfected wild-type MITF ac-
tivity on the CDK2 reporter by 80% and 90%, respectively. In These results suggest that the E2 element is not essential for
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Figure 2. Transcriptional regulation of endogenous CDK2 by MITF
A: Regulation of endogenous CDK2 mRNA levels by MITF in primary melanocytes (HPM) and melanoma cells. Total RNA was isolated 48–72 hr after infection.
Quantitative RT-PCR was performed, and data were normalized to the expression level of the control gene. CDK2 mRNA level in the control adenovirus-
infected sample was normalized to 1.
B: Regulation of CDK2 protein levels and kinase activities by MITF in primary melanocytes. CDK2 protein levels and kinase activities were assayed 72 hr
after infection.
C: Regulation of CDK2 protein levels in five melanoma cell lines where CDK2 protein levels were assayed 48 to 72 hr after infection.
D: Downregulation of CDK2 expressions by siRNA-mediated depletion of MITF in melanoma cells (SKMEL28) but not in colon carcinoma cells (SW480).
Melanoma cells are infected with retrovirus expressing control siRNA either against luciferase or against MITF. Puromycin was added to the culture media
48 hr after infection. Western analysis was performed 48 hr after selection.
CDK2 promoter activity in MITF-negative cells, which is consis- specific regulation of CDK2 expression by MITF in the melano-
cyte lineage.tent with the results presented in Figure 4.
Lack of transcriptional regulation of CDK2 Functional rescue by CDK2 after disruption of MITF
in colony formationby MITF in nonmelanocytes
We previously found that MITF could modulate SILV transcrip- To assess the functional importance of MITF’s regulation of
CDK2 expression, colony growth assays were performed usingtion in both nonmelanocytes and melanocytes (Du et al., 2003).
We therefore asked whether CDK2 could be regulated by MITF dominant-negative MITF (dn) (Widlund et al., 2002), which local-
izes to the nucleus (Figure 5A) and represses basal activityin nonmelanocytes as well. CDK2 mRNA levels were examined
in WI-38 fibroblasts after infection with adenovirus expressing a of an E box-driven reporter (Figure 5B). Sublethal doses of
dominant-negative MITF suppressed melanoma colony forma-control protein or wild-type MITF. In contrast to the upregulation
observed in the melanocyte lineage (Figure 2A), no significant tion by nearly 70% (Figure 5C). However, this suppression was
rescued by overexpression of CDK2. In the reciprocal experi-difference in CDK2 mRNA levels was seen in these fibroblasts
(Figure 4A). Consistent with previously published data (Du et ment (Figure 5D), dominant-negative CDK2 disrupted colony
formation but was not rescued by wild-type MITF overexpres-al., 2003), we observed a significant upregulation of SILV mRNA
upon wild-type MITF expression in these fibroblasts (Figure 4A). sion. These data suggest that disruption of MITF produces a
block to cell growth due to depletion of CDK2, consistent withIn addition, MITF had no effect on CDK2 reporter activity when
cotransfected into 293, SW480, or T47D (Figure 4B and data the model that CDK2 may be a functionally critical downstream
effector of MITF for cell proliferation in melanoma cells. Thenot shown), nor was the E2 site important for basal expression
(Figure 4C and data not shown). These data suggest a tissue- data also suggest that suppression of CDK2 is measurably dele-
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Figure 3. MITF modulates CDK2 transcription via an E box (E2) within the enhancer element
A: Reporter assays of CDK2 point mutants. CDK2 reporters with point mutations were transfected into 501mel melanoma. Firefly luciferase activities in
samples were normalized to Renilla luciferase activities in the same specimens. Ratios between firefly and Renilla luciferase (transfection efficiency control)
activities are shown.
B: Dominant-negative but not null MITF mutants disrupt transactivation of CDK2 reporter (pCDK2-E1E2) by the wild-type protein. The wild-type CDK2 reporter
was transfected into 501mel cells in the presence of wild-type MITF plus vector control or Mitf mutant (Mitf Mi-or, Mitf Mi-mi, or Mitf mi-ce ). The transfections were
performed in triplicate, and standard errors are indicated with bars. The data are shown as percent wild-type MITF activity on the human CDK2 reporter
after subtracting vector-only control. The belly spot phenotypes of corresponding heterozygous Mitf mutant are presented underneath. Wild-type MITF
activity was repressed by MitfMi-or and MitfMi-mi (with belly spots) but not Mitfmi-ce (no belly spot).
C: Colony formation assay of pCDK2-puro constructs. Vectors expressing puromycin resistance gene driven by the CDK2 promoter-enhancer were con-
structed and transfected into 501mel (melanoma) or SW480 (nonmelanoma) as described in the Experimental Procedures section. Number of colonies
were counted 2 weeks postselection and are shown together with a representative example.
terious to melanoma cell growth, although complementary ap- correlation was computed as described in the Experimental
Procedures section. Of the 16,063 genes analyzed, CDK2 wasproaches are required to reach this conclusion (see below),
since the CDK2(dn) could theoretically carry out CDK2-indepen- significantly correlated to MITF in the ten primary melanomas
(p  0.01) (Figure 6B). Importantly, CDK2 was not significantlydent inhibitory activities.
correlated with MITF in nonmelanoma tumors (shown for lym-
phomas in Figure 6C). We also examined the protein levels ofCorrelation of CDK2 and MITF expression in human
melanoma cell lines and primary human melanomas MITF and CDK2 in these nine melanoma cell lines and observed
a correlation in protein expression. In contrast, the expressionbut not other cancers
As an independent means of examining the relevance of CDK2 levels of three additional cyclin-dependent kinases (CDK1,
CDK4, and CDK5) lacked correlation with MITF expression inregulation by MITF in vivo, mRNA levels of MITF and CDK2 were
examined by quantitative RT-PCR in nine human melanoma cell these melanomas (Figure 6D). These observations provide inde-
pendent support for the model that MITF resides in a transcrip-lines and found to be tightly correlated (Figure 6A). In addition,
microarray expression profiling data were examined from a se- tional pathway with CDK2 selectively within the melanocyte
lineage.ries of primary human melanomas (Ramaswamy et al., 2001).
To look for genes highly correlated with endogenous MITF ex-
pression in melanomas, we identified the genes best matching MITF/CDK2 expression and sensitivity to roscovitine
The observed fluctuations in MITF and CDK2 mRNA and proteinthe MITF expression pattern using a Pearson correlation coeffi-
cient-based marker analysis algorithm. The significance of the levels among the melanoma samples (Figure 7 and data not
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Figure 4. MITF does not regulate CDK2 transcrip-
tion in nonmelanocytes
A: Endogenous CDK2 mRNA levels are not af-
fected, while SILV mRNA levels are modulated
by MITF overexpression in WI-38 fibroblasts. Total
RNA was isolated 72 hr after infection. Quantita-
tive RT-PCR was performed, and data were nor-
malized to the expression level of the control
gene. CDK2 and SILV mRNA levels in the con-
trol adenovirus-infected sample was normalized
to 1.
B: In SW480 cells, MITF transactivates SILV but not
CDK2 reporters in an E box-dependent fashion.
Firefly luciferase activities in samples were nor-
malized to Renilla luciferase activities in the same
specimens. Relative luciferase activities are
shown. The relative activities of control (vector)-
stimulated reporters are normalized to 1.
C: Mutation of the E2 element lowers basal re-
porter activities in melanoma cells but has no
effects in nonmelanocytes. CDK2 reporters were
transfected into 501mel (melanoma) or SW480
cells (nonmelanoma), and luciferase activities
were analyzed 48 hr after transfection. Firefly lu-
ciferase activities in samples were normalized to
Renilla luciferase activities in the same speci-
mens. The relative activities of pCDK2-E1E2 are
normalized to 1 in both cell types.
shown) led us to ask whether expression level differences may CDK2 protein expression as well as functionally reducing its
kinase activity in transduced cells (Figure 8A). To investigatebe associated with altered sensitivity to CDK2 inhibitors and
thereby predict treatment response for melanoma subsets. To whether the CDK2 depletion affects cell proliferation and/or cell
death, we then performed cell cycle analysis, short-term celltest this hypothesis, melanoma cell lines were treated with dose
titrations of the CDK2 inhibitor roscovitine (Rudolph et al., 1996), growth, and apoptosis assays upon introduction of retrovirus
expressing siRNA against CDK2 in various melanoma lines (asand LD50’s were determined. Roscovitine inhibits CDK2/cyclinA
and CDK2/cyclinE complexes by competing for the ATP binding compared to a control siRNA directed against the luciferase
gene). FACS analysis showed CDK2 siRNA results in significantdomain in the kinase subunit. As shown in Figure 7, CDK2
expression correlated virtually perfectly with LD50 and indicated reduction of the S phase population in the five melanoma lines
tested (Figure 8B). In addition, short-term growth was pro-that lower CDK2 expression is associated with enhanced drug
sensitivity, whereas high CDK2 expression confers relatively foundly inhibited in these cells (Figure 8C and data not shown).
On the other hand, we did not observe a large difference inhigh resistance. In addition, we observed that SW480, a colon
carcinoma cell line, appeared to be relatively resistant to roscov- cell death (data not shown), suggesting that CDK2 is primarily
involved in melanoma proliferation, rather than survival. We alsoitine despite low CDK2 expression (Figure 7), consistent with
previously published data that CDK2 is dispensable for the pro- carried out colony growth assays in A375 melanoma cells.
siRNA-mediated CDK2 depletion virtually abolished colonyliferation of these cells (Tetsu and McCormick, 2003). While
numerous additional variables determine clinical responsiveness growth (Figure 8D). As a control, we performed the same experi-
ment with the colon carcinoma cell line SW480. Consistentto antineoplastic agents, these data are consistent with the
model that the unique regulation of CDK2 by MITF in melanomas with the results obtained by Tetsu and McCormick (2003), we
observed no significant difference in SW480 colony growth uponis associated with a unique pattern of susceptibility to a new
class of experimental therapeutics. CDK2 downregulation (Figure 8D). These results are consistent
with the possibility that melanoma cells behave differently than
other cancers, such as colon carcinoma cells, in terms of a func-A critical role of CDK2 on melanoma growth
and proliferation tional requirement for CDK2 activity for cell cycle progression.
Recent results show that CDK2 is not essential for the prolifera-
tion of colon carcinomas and cells from several other cancer Discussion
types (Tetsu and McCormick, 2003). In addition, Cdk2 knockout
animals show no dramatic phenotypes other than sterility (Ber- Here, we show that CDK2 is important for melanoma growth
and proliferation. CDK2 has long been thought to be one of thethet et al., 2003; Ortega et al., 2003). However, ectopically ex-
pressed dominant-negative CDK2 produced a profound pheno- key cell cycle regulators in the G1-S transition. However, its
role has been challenged by three recent reports (Berthet et al.,type of G1-S arrest in several melanoma cell lines tested (data
not shown), as well as suppression of clonogenic growth (Figure 2003; Ortega et al., 2003; Tetsu and McCormick, 2003). In colon
cancer cell lines, CDK4 but not CDK2 inhibition is sufficient to5D). We therefore asked whether CDK2 might be of particular
importance to melanoma growth. Toward this end, we designed cause cell cycle arrest following inhibition of the MAPK pathway
(Tetsu and McCormick, 2003). Moreover, inhibition of CDK2a siRNA against CDK2 which could effectively knock down
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Figure 5. CDK2 resides downstream of MITF in melanoma colony growth assays
A: Immunofluorescence shows nuclear localization of DAPI (nuclei) and FITC (dominant-negative [dn] mutant of MITF) in 501mel melanoma cells.
B: Reporter assays of 4x E box in human 501mel melanoma cells show repression of basal transcription by dnMITF.
C: Rescue of MITF(dn) colony suppression by CDK2(wt). All experiments were done in triplicate. MITF(dn) expression vector was cotransfected with either
control pcDNA3.1 or CDK2(wt) expression vector into 501mel cells. Puromycin was added to cultured media 48 hr posttransfection. Cells were stained with
crystal violet once visible colonies appeared (50 cells). Colonies were counted manually. Numbers of colonies are shown together with standard error.
D: Repression of colony formation by dominant-negative CDK2. CDK2(dn) expression vector was cotransfected with either control pcDNA3.1 or MITF(wt)
expression vector into 501mel cells. Numbers of colonies are presented together with standard error.
with CDKN1B/p27KIP1, a dominant-negative CDK2, siRNA, or tant cell cycle regulator in melanoma cells. Inhibition of CDK2
thus warrants consideration as a therapeutic approach for mela-antisense against CDK2 did not prevent cell proliferation in these
cells as well as several osteosarcomas and RB1-negative cervi- nomas, especially given the profound tolerance of the wild-type
host to CDK2 suppression in the knockout setting.cal cancer cell lines (Tetsu and McCormick, 2003). Our data
also suggest that CDK2 is dispensable for colon carcinoma Cdk2 null mice from Ortega et al. (2003) and Berthet et al.
(2003) show no obvious coat color phenotype. This suggestsgrowth (Figure 8D). On the other hand, CDK2 appears to be of
particular importance to human melanoma cells. Depletion of that CDK2 is dispensable or that its function may be compen-
sated for by other unknown factors during normal melanocyteCDK2 with siRNA strongly suppressed colony growth of mela-
noma cells (Figure 8D). When CDK2 is partially depleted with development. Although human melanocytes that give rise to
most cutaneous melanomas are thought to derive from epider-retrovirus infection, both melanoma S phase population and
growth rate are significantly reduced (Figures 8B and 8C). We mal compartment (differing from mice, in which melanocytes
do not permanently reside in epidermis), the apparently normalalso found that blocking CDK2 with a dominant-negative mutant
suppressed colony-forming activity of melanoma cells (Figure hair follicle phenotype suggests that no major melanocytic de-
fect is associated with CDK2 loss. It is therefore anticipated5D). In addition, overexpression of dominant-negative CDK2
arrested melanoma cells in G1-phase (data not shown). To- that siRNA against CDK2 would have little effect on cultured
human primary melanocytes based on the in vivo data and thegether, these results suggest that CDK2 behaves as an impor-
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Figure 6. Correlations between MITF and CDK2
mRNA and protein levels in human melanomas
A: Correlations in human melanoma cell lines.
Total RNA was extracted, and transcript levels of
both genes were measured as described in the
Experimental Procedures. Expression levels were
normalized to that of ACTB (-actin). The raw
expression value for each gene was normalized
to a mean of zero and standard deviation of
one.
B: Correlations in human primary melanomas.
Quantitative mRNA levels for both genes in ten
primary melanomas were acquired from Affy-
metrix microarrays as described in the Experi-
mental Procedures. The raw expression value for
each gene was normalized to a mean of zero
and standard deviation of one. Also see Experi-
mental Procedures for p value calculation.
C: Lack of correlations in human lymphomas. Ex-
pression levels of CDK2 and MITF were acquired
from Affymetrix microarrays. The raw expression
value for each gene was normalized to a mean
of zero and standard deviation of one.
D: Correlations at the protein level in human mel-
anoma cell lines and lack of correlation for CDK1,
CDK4, and CDK5.
fact that these cells are cycling very slowly and contain high tumor types examined by Tetsu and McCormick (2003), al-
though it is formally possible that similar behavior may be dis-levels of CDK2 and MITF.
CDK2 functions during the G1-S transition though RB1 covered in other lineages. It is unclear at this stage how this
comes about, or for that matter how other cell types survivephosphorylation and in S phase via regulation of DNA replication
(Ekholm and Reed, 2000). Our results suggest that CDK2 is without CDK2. Along these lines, we have examined the NCI-
60 tumor cell line mRNA and protein expression databasesimportant for melanoma proliferation but do not distinguish be-
tween RB1-mediated G1 arrest versus blockage at other phases (Staunton et al., 2001 and http://dtp.nci.nih.gov/mtargets/
mt_index.html) for CDK2 levels and found that both mRNA andof the cell cycle. It will be interesting to see whether CDK2
depletion affects RB1 phosphorylation status in melanoma cells. protein levels of CDK2 were particularly high in melanomas, as
compared to all nonmelanoma cancers, in a statistically signifi-Also, it will be interesting to study the effects of siCDK2 in a
RB1 null setting in order to clarify the precise role of CDK2 in cant fashion (p  0.05; data not shown). It is plausible that high
CDK2 expression in melanomas is a consequence of turningthese cells.
One implication of the observations reported here is that on SILV transcription in these cells, since both genes share
the same enhancer element. Alternatively, CDK2 might performCDK2 function is unique in melanoma, as compared to other
Figure 7. Sensitivities of melanoma cell lines to
CDK2 inhibitor roscovitine correlate with endog-
enous CDK2 expression levels
Cell viability was measured at OD450 after WST-1
assay. LD50 for each cell line was obtained as
described in the Experimental Procedures. The
left panel presents the LD50 of various cell lines
toward roscovitine. CDK2 expression levels in
these cell lines are indicated at the bottom (low-
est expression [] to highest []). The right
panel presents representative response curves
toward roscovitine in two melanoma cell lines.
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Figure 8. Effects of siRNA against CDK2 on mela-
noma growth and proliferation
A: siRNA against CDK2 downregulates CDK2 ex-
pression and kinase activity in melanoma cells.
Western analysis and kinase assay were per-
formed on melanoma lysates from cells infected
with retrovirus expressing siRNA either against lu-
ciferase or against human CDK2.
B: Depletion of CDK2 decreases S phase popula-
tion in melanoma cells.
C: Depletion of CDK2 slows down short-term pro-
liferation of melanoma cells.
D: Downregulation of CDK2 dramatically re-
duced colony growth in melanoma (A375) but
not colon carcinoma cells (SW480). Growth of
cells transfected with control siLuc vectors is nor-
malized to 100% for both lines.
different functional roles in melanomas, where higher levels of as well (Englaro et al., 1995; McGill et al., 2002; Price et al.,
1998).CDK2 may contribute to proliferation and/or growth.
It is noteworthy that, unlike many other melanocytic markers,MITF appears to modulate CDK2 expression in a melano-
MITF is expressed in nearly all human melanomas (Chang andcyte-specific manner, which is likely linked to its transcriptional
Folpe, 2001), including nonpigmented ones. This observationregulation of SILV/PMEL17/GP100. It is important that CDK2
suggests that MITF is critical to proliferation and/or survival.expression in nonmelanocytes appears to be independent of
This possibility defines a role for MITF beyond regulation ofMITF (Figure 4A). In addition, reporter assays in nonmelanocytes
melanocyte differentiation genes. One potential contributor toindicated that the E box element to which MITF binds in melano-
MITF’s survival effect appears to be BCL2, which is transcrip-
cytes is irrelevant to basal CDK2 promoter activity and does tionally regulated by MITF and whose knockout produces post-
not confer MITF responsiveness (Figures 4B and 4C). These natal melanocyte loss (McGill et al., 2002; Veis et al., 1993).
observations suggest that CDK2 expression is regulated in a However, BCL2 is unlikely to fully account for MITF’s viability
fundamentally distinct fashion in the melanocyte lineage, where function in melanoma cells, since BCL2 overexpression is inca-
it is potentially subject to fluctuations in MITF expressions. For pable of rescuing melanoma clonogenic growth in the setting of
example, melanocyte-stimulating hormone (MSH) and WNT sig- MITF disruption (McGill et al., 2002). CDK2 is thus an attractive
naling pathways are known to regulate MITF expression within candidate to help explain the essential role of MITF in melanoma
cells.melanocytes and may thus indirectly affect CDK2 expression
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CDK2 reporter construct mutagenesisIn this study, we found that downregulation of MITF re-
Site-directed mutagenesis was performed using the QuickChange methodpresses colony formation by melanoma cells, suggesting that
(Stratagene) according to the supplier’s recommendations. MutagenesisMITF may be required for melanoma growth/survival. This re-
primers were designed as follows: E1, 5-CTGGGACTACAGGGAGGTGC
pression could be rescued by overexpression of wild-type CACCATGCC-3 and 5-GGCATGGTGGCACCTCCCTGTAGTCCCAG-3;
CDK2, suggesting that CDK2 is one of MITF’s downstream E2, 5-CCCAGAGCCCTTTGAGGTGATGCTCAGCT-3 and 5-AGCTGAGC
ATCACCTCAAAGGGCTCTGGG-3.effectors essential to cellular proliferation. Together, the current
work identifies CDK2 as a cell cycle-related target gene and also
Transfection and dual luciferase reporter assaysuggests that its modulation by MITF is functionally important
CDK2 and pGL2-4xE-box (Hemesath et al., 1994) reporter constructs were
to melanoma growth. Thus, the identification of CDK2 as a transfected using Fugene 6 (Roche) together with either pRC-CMV/MITF(wt)
transcriptional target of MITF in melanocytes highlights a newly (encoding full-length M-form human MITF), pRC-CMV/MITF(mutant) (encod-
ing murine M-form MITF lacking amino acid Arg218) (Hemesath et al., 1994;identified role for MITF in support of the cell cycle machinery.
Motyckova et al., 2001; Wu et al., 2000) or pcDNA3.1 (Invitrogen) and pRLMoreover, our results suggest that CDK2 might be particularly
null (Promega). A total of 1 g DNA was used for each transfection. Cellimportant for melanoma proliferation. These observations not
lysates were prepared 48 hr after transfection, the activities of firefly and
only help explain MITF’s essential role in melanoma growth but Renilla luciferase were assayed using a Dual Luciferase kit (Promega) ac-
also support CDK2 as a potential drug target for melanoma cording to the manufacturer’s recommendations, and signals were normal-
ized for transfection efficiency to the internal Renilla controls.therapy. Moreover, the unique regulation of CDK2 transcription
in melanoma, correlating between CDK2 (also MITF) expression
pPL3-CDK2 constructs and colony formation assayand drug sensitivity, may help predict patients’ responses to
The pPL3-CDK2 vectors (with puromycin resistance) were constructed byCDK2-targeted cancer treatment.
replacing the luciferase coding sequence in corresponding luciferase report-
ers with puromycin CDS from pLPCX (Clontech). Colony growth assay was
Experimental procedures performed by transfecting 6 g pCDK2-puro plasmid per well of 501mel in
6-well plates. Each transfection was done in triplicate. Puromycin was added
Cell culture and media to the media 24 hr posttransfection. Numbers of colonies were counted after
501mel was a gift from Dr. Ruth Halaban (Yale Medical School) and was fixation and crystal violet staining 14 days postselection.
maintained in Ham’s F10 medium supplemented with 10% FBS. MeWo,
SKMEL5, A375 melanomas, and WI-38 fibroblasts were purchased from ChIP
ATCC. All other melanoma cell lines (M14, SKMEL28, UACC62, MALME- ChIP assays were performed with cells grown to logarithmic phase. Cells
3M, UACC257, and SKMEL2) were obtained from NCI. SW480 colon carci- were harvested by scraping, homogenized in a hypotonic buffer (10 mM
noma was a gift from Eric Fearon. SKMEL5, A375, and SW480 were cultured Tris-HCl [pH 7.4], 15 mM NaCl, 60 mM KCl, 1 mM EDTA, 0.1% Nonidet
in DMEM with 10% FBS. All melanoma lines from NCI were maintained in P40, 5% sucrose, 1	 complete proteinase inhibitor cocktail [Roche]) on ice
RPMI with 10% FBS. MeWo was cultured in Ham’s F10 with 10% FBS. WI- using a Dounce homogenizer. The nuclei were isolated by centrifugation
38 was cultured in MEM (Mod.) with 10% FBS. Human primary melanocytes onto a 10% sucrose pad and then crosslinked with 1% formaldehyde in
were purchased from Clonetics or provided by Dr. Ruth Halaban and main- PBS for 20 min at room temperature with gentle shaking. Nuclei were then
tained in TICVA medium (F10 with penicillin/streptomycin/glutamine, 7.5% spun down and resuspended in ChIPs buffer (10 mM Tris-HCl [pH 7.4], 100
FBS, 50 ng/ml TPA, 225 M IBMX, 1 M Na3VO4, and 1 mM dbcAMP). mM NaCl, 60 mM KCl, 0.1% Nonidet P40, 1	 complete proteinase inhibitor
cocktail [Roche]) and sonicated by two 1 min pulses on ice using a Fisher
dismembranator fitted with a microtip. Antibodies (rabbit anti-MITF, rabbitMicroarray and gene correlation analyses
anti-BRN2 [sc-6029X; Santa Cruz], or rabbit anti-CDK2 [H-298; Santa Cruz])Expression profiling data on human primary tumors were collected using
were then added to a 10-fold ChIPs buffer diluted sample and incubatedAffymetrix Hu6800 and Hu35KsubA high-density oligonucleotide microar-
on a nutator for 3 hr at room temperature. Ultralink protein-A/G-beadsrays as described elsewhere (Ramaswamy et al., 2001). Here, we specifically
(Pierce) were added to the sample and a control sample and incubated forlooked at primary melanomas and lymphomas. Expression values were given
an additional hour. Immunoprecipitates were then washed twice with ChIPsa lower threshold of 10 units and a ceiling of 16,000 units. For marker
buffer, twice with 500 mM NaCl ChIPs buffer, and once with TE (pH 8). Theanalyses, the data set was filtered to eliminate genes whose expression
immunoprecipitates were released from the beads by incubating at 65
C forlevels did not vary more than 5-fold or 50 absolute units across the data
20 min in 1% SDS/TE and protein digested by proteinase K treatment sideset. Of the 16,063 genes on the microarray, 11,187 and 13,177 genes passed
by side with an additional unprecipitated sample as input control. Crosslinksthis filter for the melanoma and lymphoma analyses, respectively. Marker
were released by heating at 70
C for 10 hr, and DNA was recovered byanalyses were performed using the Pearson correlation coefficient to identify
extraction with phenol and chloroform at high-salt (0.6 M Na Acetate [pHgenes with similar patterns of expression to MITF across the melanoma and
8]) and then ethanol precipitated. Semiquantitative PCR was then performed
lymphoma collections. Genes were sorted by their degree of correlation. To
on samples to amplify a fragment containing the second E box (E2) or the
assess the significance of the correlation, we permutated the tumor sample
third E box (E3) in the human CDK2/SILV transcription initiation region. The
labels 10,000 times and computed the Pearson correlation between MITF
forward and reverse primers for the E2 region are 5-CAT AAG ATA CCC
and CDK2 after each permutation. The distribution of permuted Pearson CAT TCT TTC TCC ACT T-3 and 5-GAG AAT GTG GTA TTG GGT AAG
values indicated the number of times our permuted Pearson value exceeded AAC AC-3, respectively. The primers for the E3 region are 5-CAT GGA
our experimental Pearson value, which allowed us to assign a p value to GAA CTT CCA AAA GGT GG-3 and 5-TAC TCT CCC CAG GGA GTA TAA
our observation in both the melanoma and lymphoma datasets. GT-3.
Construction of CDK2 reporters Adenovirus infection and RNA preparation
A 2.8 kb fragment containing the first exon of CDK2 and flanking sequences Adenoviruses encoding wild-type MITF, dominant-negative mutant MITF, or
was amplified from human genomic DNA (Roche) using primers 5-GCA vector control encoding a polypeptide were generated as previously de-
ATC CTA TGA CCA CGG CCT CCC AAA G-3 and 5-GTT TTC CAT GGA scribed (Miller et al., 2004). Briefly, 106 cells were plated per 100 mm plate.
TTC CAC ACC ACC CTA TAC-3. A smaller fragment was subsequently On the second day, cells were overlaid with 2 ml serum-free F10 media
amplified from the 2.8 kb fragment with primers 5-CGG GTA CCA TGC containing 10 mM MgCl2, and concentrated adenovirus was added at MOI
CTC GGC CTC CCA AGT AGT-3 and 5-GGC CAT GGA GCG CCA GCG 100. The cells were incubated at 37
C for half an hour, after which virus
AGT CGG GTC AGC-3, digested with KpnI and NcoI, and inserted into was removed and fresh full media was added. Total RNA was isolated with
RNAqueous-4PCR kit (Ambion) at 48 or 72 hr after infection.pGL3-basic vector (Promega).
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Real-time/quantitative PCR where (Brummelkamp et al., 2002). A fragment containing the H1 promoter
The real-time PCR primers for human CDK2 were 5-ATG GAG AAC TTC and the hairpin was excised from pSUPER with EcoRI and XhoI and inserted
CAA AAG GTG GA and 5-CAG GCG GAT TTT CTT AAG CG (IDT). The probes into the p(si)2-puro retrovirus vector. MEK293EBNA cells (2 	 106; Clontech)
for human CDK2 were 5-6-FAM-ATCGGAGAGGGCACGTACGGAGTTGT- were transfected with VSVG, GAGPOL expression vectors, and p(si)2-siCDK2
TAMRA (PE Biosystems). The primers for human MITF were 5-CGA GCT or p(si)2-siMITF. Supernatant was harvested from day 2 to day 8 after trans-
CAT GGA CTT TCC CTT A and 5-CTT GAT GAT CCG ATT CAC CAA A fection. Melanoma cells were infected with the 0.45 m filtered supernatant
(IDT). The probe was 5-6-FAM-CCA TCC ACG GGT CTC TGC TCT CCA in the presence of 8 g/ml polybrene for 3 hr. The retrovirus supernatant
G (PE Biosystems). The primers for human -actin (ACTB) were 5-ATT GCC was then removed, and fresh media were added to the cells. Forty-eight
GAC AGG ATG CAG AA and 5-GCT GAT CCA CAT CTG CTG GAA (IDT), hours after infection, puromycin was added at a final concentration of 2 g/
and the probe was 5-6-FAM-CAA GAT CAT TGC TCC TCC TGA GCG CA ml to select for infected cells. Western analysis, CDK2 kinase assay, FACS
(IDT). The total volume of each reaction was 25 l, including 12.5 l 2	 analysis, and cell growth assay were performed starting at 48 hr after selec-
Master Mix without UNG (uracil-N-glycosylase), 0.625l MultiScribe Reverse tion. For cell growth assay, retrovirus-infected cells were plated onto 6-well
Transcriptase and RNase inhibitor (PE Biosystems), 0.5 l of each primer plates. Triplicate samples were plated for each sample at each time point.
(10 M stock), 0.25 l of the probe (5 M stock), and 1 l of the template Cells were fixed from day 1 to day 4 after plating and stained with crystal
at 100 ng/l. Reverse transcription proceeded at 48
C for 30 min. Then, 40 violet. Cells were then destained with 500 l 10% methanol and 10% acetic
cycles of PCR reaction were carried out at 95
C for 15 s and at 60
C for 1 min. acid in PBS for each well. The OD595-750 was used as measurement for
Real-time PCR was carried out using ABI PRISM 7700 Sequence Detection cell growth.
System (Applied Biosystems) with analysis using the integrated Sequence
Detection System Software Version 1.7. Standard curves were generated CDK2 kinase assay and cell cycle analysis
for all primer sets to confirm linearity of signals over the experimentally Cells were lysed with EBC buffer (50 mM Tris [pH 8.0], 100 mM NaCl, 0.5%
measured ranges. NP-40) with phosphotase inhibitors (0.5 mM Na3VO4, 1 mM NaF, 10 mM
-glycerophosphate) and protease inhibitors (Roche) on ice for 30 min. Lysed
Western analysis cells were spun down, and protein concentration was measured with BCA
Cells were collected and lysed in 2	 lysis/loading buffer (125 mM Tris Protein Assay Kit (Pierce) according to the manufacturer’s instructions. Equal
[pH 6.8], 4.6% SDS, 20% glycerol, and 0.04% pyronin Y), resolved by amount of total protein from each sample was incubated with agarose-
electrophoresis in 12% SDS-polyacrylamide gels, and transferred to nitrocel- conjugated anti-CDK2 antibody (Santa Cruz M2) for 120 min at 4
C. Immuno-
lulose membranes (Protran from Schleicher and Schuell). All proteins were complexes were washed with NETN buffer (20 mM Tris [pH 8.0], 100 mM
detected using chemiluminescence and antibodies to CDK2 (Santa Cruz), NaCl, 1 mM EDTA, 0.5% NP-40) plus protease inhibitors and IPK buffer (50
MITF (C5), CDK1 (UpState), CDK4 (UpState), CDK5 (UpState), BCL2 (Santa mM Tris [pH 7.5], 10 mM MgCl2, 1 mM DTT) with protease inhibitors. Histone
Cruz), SILV (anti-PEP13h from Dr. Vincent Hearing), and -tubulin (Sigma). H1 (2.5 g), 20 M cold ATP, and 1 l of 10 mCi/ml -[32P]-ATP were
incubated with immunocomplexes in a 50 l reaction at 30
C for 20 min.
pcDNA3-5trMi construct and colony formation assay The samples were subjected to 12.5% SDS-PAGE. The gel was dried and
A DNA sequence encoding dominant-negative human MITF lacking the 5 subjected to autoradiography.
transactivation domain (used in colony assays; Figure 5) was cloned after For cell cycle analysis, cells were pelleted and fixed in 70% EtOH for
PCR amplification into the BamH1/EcoRI sites of pcDNA3.1 (Invitrogen) 30 min. Cells were washed with PBS once and stained with 1 mg/ml propid-
construct carrying an engineered HA-tag 5 of the basic region of MITF. ium iodide and 25 g/ml RNase in PBS for 30 min. The cell cycle profiles
501mel cells were split into 6-well plates to give a confluency of 50% on were collected with FACSCaliber with Cellquest (Becton Dickinson) and
the day of transfection. A total of 2.5 g (for wt-MITF and dn-CDK2) or analyzed with ModFit (Verity Software House) software.
5 g (for dn-MITF and wt-CDK2) DNA including 10% pBabe-puro was
transfected per well using Fugene6. For Figure 8, A375 and SW480 cells
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